Evofem Biosciences Probability of Future OTC Stock Price Finishing Over 0.0479
| EVFMDelisted Stock | USD 0.05 0.0001 0.21% |
Evofem |
Evofem Biosciences Target Price Odds to finish over 0.0479
The tendency of Evofem OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.05 | 90 days | 0.05 | roughly 96.0 |
Based on a normal probability distribution, the odds of Evofem Biosciences to move above the current price in 90 days from now is roughly 96.0 (This Evofem Biosciences probability density function shows the probability of Evofem OTC Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Evofem Biosciences has a beta of -1.58 suggesting as returns on its benchmark rise, returns on holding Evofem Biosciences are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Evofem Biosciences is expected to outperform its benchmark. Additionally Evofem Biosciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Evofem Biosciences Price Density |
| Price |
Predictive Modules for Evofem Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Evofem Biosciences. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Evofem Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Evofem Biosciences is not an exception. The market had few large corrections towards the Evofem Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Evofem Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Evofem Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.55 | |
β | Beta against Dow Jones | -1.58 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | -0.12 |
Evofem Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Evofem Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Evofem Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Evofem Biosciences is not yet fully synchronised with the market data | |
| Evofem Biosciences has some characteristics of a very speculative penny stock | |
| Evofem Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Evofem Biosciences currently holds 125.74 M in liabilities with Debt to Equity (D/E) ratio of 8.72, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evofem Biosciences has a current ratio of 0.16, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Evofem Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Evofem Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Evofem Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Evofem to invest in growth at high rates of return. When we think about Evofem Biosciences' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 8.24 M. Net Loss for the year was (205.19 M) with profit before overhead, payroll, taxes, and interest of 4.19 M. | |
| Evofem Biosciences currently holds about 19.89 M in cash with (146.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Evofem Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Evofem OTC Stock often depends not only on the future outlook of the current and potential Evofem Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Evofem Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 125.2 M | |
| Cash And Short Term Investments | 7.7 M |
Evofem Biosciences Technical Analysis
Evofem Biosciences' future price can be derived by breaking down and analyzing its technical indicators over time. Evofem OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Evofem Biosciences. In general, you should focus on analyzing Evofem OTC Stock price patterns and their correlations with different microeconomic environments and drivers.
Evofem Biosciences Predictive Forecast Models
Evofem Biosciences' time-series forecasting models is one of many Evofem Biosciences' otc stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Evofem Biosciences' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.
Things to note about Evofem Biosciences
Checking the ongoing alerts about Evofem Biosciences for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Evofem Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Evofem Biosciences is not yet fully synchronised with the market data | |
| Evofem Biosciences has some characteristics of a very speculative penny stock | |
| Evofem Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Evofem Biosciences currently holds 125.74 M in liabilities with Debt to Equity (D/E) ratio of 8.72, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evofem Biosciences has a current ratio of 0.16, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Evofem Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Evofem Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Evofem Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Evofem to invest in growth at high rates of return. When we think about Evofem Biosciences' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 8.24 M. Net Loss for the year was (205.19 M) with profit before overhead, payroll, taxes, and interest of 4.19 M. | |
| Evofem Biosciences currently holds about 19.89 M in cash with (146.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in census. Note that the Evofem Biosciences information on this page should be used as a complementary analysis to other Evofem Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Evofem OTC Stock
If you are still planning to invest in Evofem Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evofem Biosciences' history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |